[go: up one dir, main page]

PE20081201A1 - Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno - Google Patents

Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno

Info

Publication number
PE20081201A1
PE20081201A1 PE2007001714A PE2007001714A PE20081201A1 PE 20081201 A1 PE20081201 A1 PE 20081201A1 PE 2007001714 A PE2007001714 A PE 2007001714A PE 2007001714 A PE2007001714 A PE 2007001714A PE 20081201 A1 PE20081201 A1 PE 20081201A1
Authority
PE
Peru
Prior art keywords
crystalline form
glucopyranosyl
fluorophenyl
methyl
thyenylmethyl
Prior art date
Application number
PE2007001714A
Other languages
English (en)
Inventor
Sumihiro Nomura
Eiji Kawanishi
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38973167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of PE20081201A1 publication Critical patent/PE20081201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO QUE TIENE UN PATRON DE DIFRACCION DE RAYOS X DE POLVO QUE COMPRENDE LOS SIGUIENTES VALORES 2 MEDIDOS UTILIZANDO RADIACION CuKa: 4,36 ± 0,2; 13,54 ± 0,2; 16,00 ± 0,2; 19,32 ± 0,2 Y 20,80 ± 0,2. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE LA FORMA CRISTALINA LA CUAL ES UTIL EN EL TRATAMIENTO DE LA DIABETES MELLITUS, RETINOPATIA DIABETICA, NEFROPATIA DIABETICA, HIPERGLUCEMIA, SINDROME X
PE2007001714A 2006-12-04 2007-12-04 Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno PE20081201A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86842606P 2006-12-04 2006-12-04
JP2006327019 2006-12-04

Publications (1)

Publication Number Publication Date
PE20081201A1 true PE20081201A1 (es) 2008-09-04

Family

ID=38973167

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2007001714A PE20081201A1 (es) 2006-12-04 2007-12-04 Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
PE2011001164A PE20110841A1 (es) 2006-12-04 2007-12-04 FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
PE2013000220A PE20130591A1 (es) 2006-12-04 2007-12-04 Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2011001164A PE20110841A1 (es) 2006-12-04 2007-12-04 FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
PE2013000220A PE20130591A1 (es) 2006-12-04 2007-12-04 Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno

Country Status (34)

Country Link
US (2) US7943582B2 (es)
EP (1) EP2102224B2 (es)
JP (1) JP5159788B2 (es)
KR (1) KR101146095B1 (es)
CN (3) CN101573368B (es)
AR (4) AR064099A1 (es)
AU (1) AU2007329895C1 (es)
BR (1) BRPI0718882B8 (es)
CA (1) CA2671357C (es)
CL (1) CL2007003487A1 (es)
CO (1) CO6210719A2 (es)
CR (1) CR10861A (es)
DK (1) DK2102224T4 (es)
EA (1) EA017103B1 (es)
EC (1) ECSP099489A (es)
ES (1) ES2456640T5 (es)
GT (1) GT200900151A (es)
IL (1) IL199032A (es)
ME (1) ME01829B (es)
MX (1) MX2009005857A (es)
MY (1) MY153702A (es)
NO (1) NO344354B1 (es)
NZ (1) NZ577545A (es)
PA (1) PA8759401A1 (es)
PE (3) PE20081201A1 (es)
PL (1) PL2102224T5 (es)
PT (1) PT2102224E (es)
RS (1) RS53274B2 (es)
SI (1) SI2102224T2 (es)
SV (1) SV2009003285A (es)
TW (1) TWI403325B (es)
UY (1) UY30730A1 (es)
WO (1) WO2008069327A1 (es)
ZA (1) ZA200903941B (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
KR101552187B1 (ko) 2007-09-10 2015-09-10 얀센 파마슈티카 엔.브이. Ｓｇｌｔ 억제제로서 유용한 화합물의 제조 방법
ME02702B (me) 2008-08-22 2017-10-20 Theracos Sub Llc Postupci za pripremu inhibitora sgl t2
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
UA102429C2 (ru) 2009-02-13 2013-07-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Фармацевтическая композиция, которая включает ингибитор sglt-2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EA022186B1 (ru) * 2009-07-10 2015-11-30 Янссен Фармацевтика Нв СПОСОБ КРИСТАЛЛИЗАЦИИ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-4-МЕТИЛ-3-[5-(4-ФТОРФЕНИЛ)-2-ТИЕНИЛМЕТИЛ]БЕНЗОЛА
US8869918B2 (en) 2009-10-07 2014-10-28 Longyear Tm, Inc. Core drilling tools with external fluid pathways
UA109883C2 (uk) * 2009-10-14 2015-10-26 Спосіб отримання сполук для застосування як інгібіторів sglt2
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
CN102115468B (zh) * 2009-12-31 2014-06-11 上海特化医药科技有限公司 一种2,5-二取代噻吩化合物的合成方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011120923A1 (en) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
US20130052266A1 (en) 2010-05-11 2013-02-28 Mitsubishi Tanabe Pharma Corporation TABLETS CONTAINING A 1-(beta-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND
HRP20161231T1 (hr) * 2010-05-11 2016-11-04 Janssen Pharmaceutica N.V. Farmaceutske formulacije koje sadrže derivate 1-(beta-d-glukopiranozil)-2-tienilmetilbenzena kao sglt inhibitore
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CA2804506C (en) * 2010-07-06 2018-08-21 Janssen Pharmaceutica Nv Formulation for co-therapy treatment of diabetes
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2012140120A1 (en) * 2011-04-13 2012-10-18 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
EP2714052B1 (en) 2011-06-03 2018-09-19 Boehringer Ingelheim International GmbH Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2014530186A (ja) 2011-09-13 2014-11-17 パナセア バイオテック リミテッド 新規ｓｇｌｔ阻害剤
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20140097258A (ko) * 2011-10-31 2014-08-06 시노팜 타이완 리미티드 Sglt2 억제제의 결정성 및 비-결정성 형태
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
CN103965267A (zh) * 2013-01-24 2014-08-06 江苏豪森医药集团连云港宏创医药有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯与L-苯丙氨酸共晶物及其制备方法
ES2740299T3 (es) 2013-03-14 2020-02-05 Msd Int Gmbh Métodos para preparar inhibidores de SGLT2
JP2016512817A (ja) 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ．ベー． 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
PL2981269T3 (pl) 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
CN105358553A (zh) * 2013-05-08 2016-02-24 斯洛文尼亚莱柯制药股份有限公司 新的结晶的1-(β-D-吡喃葡萄糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的水合物
WO2014195966A2 (en) 2013-05-30 2014-12-11 Cadila Healthcare Limited Amorphous form of canagliflozin and process for preparing thereof
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
CN103641822B (zh) * 2013-10-21 2016-06-08 江苏奥赛康药业股份有限公司 一种卡格列净化合物及其药物组合物
CN103588762A (zh) * 2013-11-27 2014-02-19 苏州晶云药物科技有限公司 坎格列净的新晶型及其制备方法
WO2015071761A2 (en) * 2013-11-11 2015-05-21 Crystal Pharmatech Co., Ltd. Crystalline forms b, c, and d of canagliflozin
LT3862003T (lt) 2013-12-17 2023-12-27 Boehringer Ingelheim Vetmedica Gmbh Sglt-2 inhibitorius, skirtas naudoti taikant medžagų apykaitos sutrikimo gydymą kačių šeimos gyvūnams
RS64355B1 (sr) * 2014-01-23 2023-08-31 Boehringer Ingelheim Vetmedica Gmbh Sglt2 inhibitori za lečenje metaboličkih poremećaja kod životinja iz roda kanin
CN105939728A (zh) 2014-01-31 2016-09-14 詹森药业有限公司 用于治疗和预防肾病和脂肪肝病的方法
WO2015139386A1 (zh) * 2014-03-19 2015-09-24 杭州普晒医药科技有限公司 坎格列净一水合物及其晶型、它们的制备方法和用途
CN103980262B (zh) * 2014-04-01 2016-06-22 天津大学 卡格列净的b晶型及其结晶制备方法
CN103980261B (zh) * 2014-04-01 2016-06-29 天津大学 卡格列净的a晶型及其结晶制备方法
NZ723781A (en) 2014-04-01 2022-09-30 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
CN103896930B (zh) * 2014-04-02 2016-08-17 安徽联创生物医药股份有限公司 卡格列净半水合物药用晶型的制备方法
EP2933255A1 (en) 2014-04-17 2015-10-21 LEK Pharmaceuticals d.d. Novel crystalline form of 1-(beta-D-glucopyranosyl)-4- methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
CN103936726B (zh) * 2014-04-18 2016-06-15 王军 晶体、制备方法及其用途
CN103936800A (zh) * 2014-05-08 2014-07-23 安徽联创药物化学有限公司 1-(1-甲氧基吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的制备方法
EP2947077A1 (en) 2014-05-19 2015-11-25 LEK Pharmaceuticals d.d. Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides
CN105330706B (zh) * 2014-06-05 2019-04-16 江苏豪森药业集团有限公司 卡格列净中间体的制备方法
CN105319294B (zh) * 2014-06-20 2021-03-30 重庆医药工业研究院有限责任公司 一种分离测定卡格列净及其有关物质的方法
CN104761546A (zh) * 2014-06-21 2015-07-08 山东富创医药科技有限公司 一种新颖的 (1s)-1,5-脱氢-1-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-d-葡萄糖醇晶型及其制备方法
WO2016016774A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited Crystalline forms of canagliflozin
EP2990029A1 (en) 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
WO2016035042A1 (en) 2014-09-05 2016-03-10 Mylan Laboratories Ltd Process for the preparation of canagliflozin
CZ2014634A3 (cs) 2014-09-16 2016-03-23 Zentiva, K.S. Komplexy canagliflozinu a cyklodextrinů
HUE068152T2 (hu) 2014-09-25 2024-12-28 Boehringer Ingelheim Vetmedica Gmbh SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben
CN104402946B (zh) * 2014-11-17 2018-01-02 连云港恒运药业有限公司 卡格列净中间体及其无定形的制备方法
CN105753910A (zh) * 2014-12-16 2016-07-13 康普药业股份有限公司 一种卡格列净中间体的制备方法
CN104530023A (zh) * 2014-12-25 2015-04-22 重庆医药工业研究院有限责任公司 一种卡格列净晶型i及其制备方法
CN104945392A (zh) * 2015-01-27 2015-09-30 江苏嘉逸医药有限公司 结晶型卡格列净一水合物、制备方法及其应用
CN104530024B (zh) 2015-02-04 2017-08-08 上海迪赛诺药业有限公司 1‑(β‑D‑吡喃葡糖基)‑4‑甲基‑3‑[5‑(4‑氟苯基)‑2‑噻吩基甲基]苯的晶型及其制备方法
JP2018087140A (ja) * 2015-02-27 2018-06-07 田辺三菱製薬株式会社 １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼンの新規結晶
US10633372B2 (en) * 2015-02-27 2020-04-28 Msn Laboratories Private Limited Process for the preparation of amorphous (1S)-1,5-anhydro-1-[3-[[5-(4 fluorophenyl)-2-thienyl]-4-methylphenyl]-D-glucitol and its polymorphs thereof
WO2016142950A1 (en) * 2015-03-11 2016-09-15 Harman Finochem Limited A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form
WO2016191173A1 (en) 2015-05-22 2016-12-01 Janssen Pharmaceutica Nv Anhydrous crystalline form of (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol
CN106279134A (zh) * 2015-06-23 2017-01-04 中美华世通生物医药科技（武汉）有限公司 卡格列净单晶及其制备方法和用途
CZ2015435A3 (cs) 2015-06-25 2017-01-04 Zentiva, K.S. Pevné formy amorfního canagliflozinu
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
ES2896101T3 (es) 2015-09-15 2022-02-23 Laurus Labs Ltd Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos
WO2017064679A1 (en) * 2015-10-15 2017-04-20 Lupin Limited Process for the preparation of amorphous canagliflozin
WO2017071813A1 (en) * 2015-10-30 2017-05-04 Zaklady Farmaceutyczne Polpharma Sa Process for the preparation of a pharmaceutical agent
CZ2015824A3 (cs) * 2015-11-20 2017-05-31 Zentiva, K.S. Krystalická forma Canagliflozinu a způsob její přípravy
US10323025B2 (en) * 2015-12-21 2019-06-18 Janssen Pharmaceutica Nv Crystallization procedure for obtaining canagliflozin hemihydrate crystals
CN105541818A (zh) * 2016-03-04 2016-05-04 浙江华海药业股份有限公司 一种卡格列净水合物新晶型及其制备方法
CN107540706A (zh) * 2016-06-28 2018-01-05 山东诚创医药技术开发有限公司 伊格列净中间体的制备方法
WO2018020506A1 (en) 2016-07-25 2018-02-01 Natco Pharma Ltd Process for the preparation of amorphous form of canagliflozin
CA3041169A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
CN108017626A (zh) * 2016-11-04 2018-05-11 上海奥博生物医药技术有限公司 一种坎格列净半水合物新晶型
CN106588898A (zh) 2017-02-20 2017-04-26 浙江华海药业股份有限公司 一种卡格列净无定型的制备方法
TWI835735B (zh) 2017-06-12 2024-03-21 比利時商健生藥品公司 減少或預防第ii型糖尿病患者中心血管事件之方法
CN109553649B (zh) * 2017-09-26 2020-12-04 北大方正集团有限公司 一种卡格列净中间体的制备方法
DK3716979T3 (da) 2017-11-30 2025-06-30 Idorsia Pharmaceuticals Ltd Kombination af et 4-pyrimidinsulfamidderivat med en sglt-2-inhibitor til behandlingen af endothelinrelaterede sygdomme
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
JP7425793B2 (ja) 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
EA202191114A1 (ru) 2018-10-29 2021-09-22 Бёрингер Ингельхайм Интернациональ Гмбх Производные пиридинилсульфонамида, фармацевтические композиции и их применение
TW202103709A (zh) 2019-03-26 2021-02-01 比利時商健生藥品公司 用於治療患有慢性腎臟病之對象的方法
EP4064854A1 (en) 2019-11-28 2022-10-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors in the drying-off of non-human mammals
KR20220143732A (ko) 2020-02-17 2022-10-25 베링거잉겔하임베트메디카게엠베하 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
CN115916197A (zh) 2020-04-22 2023-04-04 拜耳公司 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合
CN113943329A (zh) * 2020-07-16 2022-01-18 尚科生物医药（上海）有限公司 一种坎格列净中间体的非对映异构体的制备方法
WO2022067724A1 (zh) 2020-09-30 2022-04-07 北京睿创康泰医药研究院有限公司 一种sglt-2抑制剂·肌氨酸共晶体及其制备方法和应用
CN114478501A (zh) * 2020-10-28 2022-05-13 杭州中美华东制药有限公司 一种制备稳定的卡格列净半水合物晶型的方法
AU2022319909A1 (en) 2021-07-28 2024-02-22 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
US20240269105A1 (en) 2021-07-28 2024-08-15 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
EP4376830A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
CN119997931A (zh) 2021-12-30 2025-05-13 纽阿姆斯特丹制药公司 Obicetrapib和SGLT2抑制剂组合
EP4531810A1 (en) 2022-05-25 2025-04-09 Boehringer Ingelheim Vetmedica GmbH Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
US20240307628A1 (en) 2023-03-06 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
WO2024226537A1 (en) 2023-04-24 2024-10-31 Newamsterdam Pharma B.V. Amorphous obicetrapib and sglt2 inhibitor combination
AU2024277852A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
WO2025224069A1 (en) 2024-04-23 2025-10-30 Bayer Aktiengesellschaft Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160861A (en) * 1977-10-03 1979-07-10 Merck & Co., Inc. Method for the separation of antibiotic macrolides
US4584369A (en) * 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
JP2544609B2 (ja) 1986-10-07 1996-10-16 和光純薬工業株式会社 Ｔｃｎｑ錯体
EP0355750B1 (en) 1988-08-19 1995-01-25 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
JPH04253974A (ja) 1991-02-05 1992-09-09 Ishihara Sangyo Kaisha Ltd スルホニル尿素系化合物、それらの製造方法及びそれらを含有する除草剤
US5149838A (en) * 1991-09-20 1992-09-22 Merck & Co., Inc. Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
GB9208161D0 (en) 1992-04-14 1992-05-27 Pfizer Ltd Indoles
US5334225A (en) 1992-07-15 1994-08-02 Kao Corporation Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US6297363B1 (en) * 1993-02-12 2001-10-02 Nomura Co., Ltd. Glycoside indoles
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
CA2236007A1 (en) 1995-10-31 1997-07-17 Gerald Floyd Smith Antithrombotic diamines
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JPH09263549A (ja) 1996-01-25 1997-10-07 Fujisawa Pharmaceut Co Ltd ベンゼン誘導体の製造法
TW406086B (en) * 1996-12-26 2000-09-21 Tanabe Seiyaku Co Propiophenone derivatives and process for preparing the same
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JPH10324632A (ja) 1997-03-25 1998-12-08 Takeda Chem Ind Ltd 医薬組成物
JP2000034239A (ja) 1998-07-16 2000-02-02 Asahi Glass Co Ltd トリフルオロメチル化芳香族化合物の製造方法
JP3857429B2 (ja) 1998-07-17 2006-12-13 ポーラ化成工業株式会社 含硫黄抗真菌剤
US20020032164A1 (en) * 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
BR0108908A (pt) 2000-03-03 2002-12-24 Pfizer Prod Inc Derivados de éteres de pirazol como agentes antiinflamatórios/analgésicos
US7465712B2 (en) 2000-03-17 2008-12-16 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
AU2002210990A1 (en) 2000-11-02 2002-05-15 Ajinomoto Co. Inc. Novel pyrazole derivatives and diabetes remedies containing the same
US6476352B2 (en) * 2000-12-18 2002-11-05 General Electric Company Laser beam stop sensor and method for automatically detecting the presence of laser beam stop material using a laser beam stop sensor
DE60138768D1 (de) * 2000-12-28 2009-07-02 Kissei Pharmaceutical Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
JP4141258B2 (ja) * 2001-02-26 2008-08-27 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体及びその医薬用途
JP4147111B2 (ja) * 2001-02-27 2008-09-10 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体およびその医薬用途
CA2439448C (en) 2001-03-02 2012-05-22 University Of Western Ontario Polymer precursors of radiolabeled compounds, and methods of making and using the same
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
DK1385856T3 (da) * 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
EP1389621A4 (en) * 2001-04-27 2005-05-11 Ajinomoto Kk N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
GB0112122D0 (en) 2001-05-18 2001-07-11 Lilly Co Eli Heteroaryloxy 3-substituted propanamines
EP1405859A4 (en) 2001-06-20 2008-01-23 Kissei Pharmaceutical NITROGENIC HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, MEDICAL USE AND INTERMEDIATE PRODUCTS CONTAINING THEREOF
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
WO2003011880A1 (fr) 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
EP1432720A1 (en) * 2001-09-05 2004-06-30 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
ATE312940T1 (de) * 2001-10-24 2005-12-15 Michael Burton Chromogenischen enzymsubstraten und verfahren zum nachweis von beta-d-ribofuranosidase-wirksamkeit
EA009281B1 (ru) 2001-11-16 2007-12-28 Катаникс Корпорейшн Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
US6617313B1 (en) * 2002-03-13 2003-09-09 Council Of Scientific And Industrial Research Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof
US6562791B1 (en) * 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
HK1080470B (zh) 2002-04-18 2008-03-07 Astrazeneca Ab 杂环化合物
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
CN100341885C (zh) 2002-08-09 2007-10-10 大正制药株式会社 选择性制备芳基5－硫代－β－D－吡喃己醛糖苷的方法
WO2004018442A1 (en) 2002-08-23 2004-03-04 Dr. Reddy's Laboratories Limited Crystalline and amorphous forms of (s) -repaglinide and the processes for preparation thereof
JP4606876B2 (ja) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
BR0317929A (pt) * 2003-01-03 2006-04-11 Bristol Myers Squibb Co métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
US7202350B2 (en) 2003-03-14 2007-04-10 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
ES2377741T3 (es) 2003-06-20 2012-03-30 Kissei Pharmaceutical Co., Ltd. Derivados de pirazol, composición farmacológica que los contiene e intermedios de producción de los mismos
CA2549022A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
EP1679965A4 (en) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
CA2549025A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
EA010655B1 (ru) * 2003-08-01 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индазол-о-глюкозиды
DK1651658T4 (da) 2003-08-01 2020-11-09 Mitsubishi Tanabe Pharma Corp Nye forbindelser med hæmmende aktivitet mod natriumafhængig transporter
UA86042C2 (en) * 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
US20070021430A1 (en) 2003-09-23 2007-01-25 Chen Alex M Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
CA2605245A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007035198A2 (en) 2005-07-25 2007-03-29 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
WO2007054978A2 (en) 2005-11-10 2007-05-18 Jubilant Organosys Limited Process for preparing paroxetine hydrochloride hemihydrate
EP1842850A1 (en) 2006-03-23 2007-10-10 Sandoz AG Rosiglitazone hydrochloride hemihydrate
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
KR101552187B1 (ko) † 2007-09-10 2015-09-10 얀센 파마슈티카 엔.브이. Ｓｇｌｔ 억제제로서 유용한 화합물의 제조 방법

Also Published As

Publication number Publication date
DK2102224T4 (da) 2021-10-11
BRPI0718882B8 (pt) 2021-05-25
JP5159788B2 (ja) 2013-03-13
SI2102224T2 (sl) 2021-11-30
KR101146095B1 (ko) 2012-05-16
SI2102224T1 (sl) 2014-03-31
AU2007329895C1 (en) 2014-03-13
RS53274B (en) 2014-08-29
EA200970540A1 (ru) 2009-10-30
US8513202B2 (en) 2013-08-20
US20080146515A1 (en) 2008-06-19
WO2008069327A1 (en) 2008-06-12
NO20091778L (no) 2009-09-04
JP2010511602A (ja) 2010-04-15
US7943582B2 (en) 2011-05-17
CN101573368B (zh) 2012-06-20
SV2009003285A (es) 2010-08-17
AR129907A2 (es) 2024-10-09
PT2102224E (pt) 2014-04-07
CN102675299A (zh) 2012-09-19
AR107510A2 (es) 2018-05-09
NZ577545A (en) 2011-08-26
ES2456640T3 (es) 2014-04-23
US20110212905A1 (en) 2011-09-01
DK2102224T3 (da) 2014-04-22
PL2102224T3 (pl) 2014-07-31
MY153702A (en) 2015-03-13
ES2456640T5 (es) 2021-12-02
CL2007003487A1 (es) 2008-03-14
IL199032A (en) 2012-12-31
ECSP099489A (es) 2009-08-28
PE20110841A1 (es) 2011-11-24
CA2671357C (en) 2011-11-01
CN101573368A (zh) 2009-11-04
CO6210719A2 (es) 2010-10-20
AU2007329895A1 (en) 2008-06-12
TW200829259A (en) 2008-07-16
BRPI0718882B1 (pt) 2021-03-23
AR064099A1 (es) 2009-03-11
CR10861A (es) 2009-07-17
ZA200903941B (en) 2010-08-25
PE20130591A1 (es) 2013-05-12
EP2102224B2 (en) 2021-08-04
KR20090086282A (ko) 2009-08-11
AU2007329895B2 (en) 2011-09-08
CA2671357A1 (en) 2008-06-12
PA8759401A1 (es) 2009-04-23
AR118450A2 (es) 2021-10-06
GT200900151A (es) 2012-01-17
UY30730A1 (es) 2008-07-03
EP2102224B1 (en) 2014-02-12
RS53274B2 (sr) 2021-10-29
NO344354B1 (no) 2019-11-11
MX2009005857A (es) 2009-06-12
ME01829B (me) 2014-12-20
CN102675380A (zh) 2012-09-19
EP2102224A1 (en) 2009-09-23
EA017103B1 (ru) 2012-09-28
BRPI0718882A2 (pt) 2014-09-16
PL2102224T5 (pl) 2021-11-08
TWI403325B (zh) 2013-08-01

Similar Documents

Publication Publication Date Title
PE20081201A1 (es) Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
AR053720A1 (es) Forma cristalina de 1-cloro-4-((beta)-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, un metodo para su preparacion y el uso del mismo para preparar medicamentos
PE20090938A1 (es) Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20080251A1 (es) Usos de inhibidores de dpp iv
PE20121046A1 (es) Terapia de combinacion para el tratamiento de la diabetes
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
ECSP10010160A (es) Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
CL2008002424A1 (es) Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido; y uso de la composicion farmaceutica para el tratamiento de la diabetes mellitus, tolerancia anormal a la glucosa e hiperglucemia, trastornos metabolicos, entre otras.
PE20060425A1 (es) Formulacion de tableta revestida que comprende saxagliptina
CL2011000382A1 (es) Uso de una composicion inmunogenica que comprende una cantidad eficaz de un virus de sindrome disgenesico y respiratorio porcino (prrs) tipo ii para disminuir la incidencia, gravedad o prevenir los efectos de una enfermedad con fiebre alta de prrs.
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
CL2007001530A1 (es) Compuestos derivados de tiazol, inhibidores de fbpasa; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de diabetes mellitus tipo i, ii y iii, desequilibrio de glucosa en ayunas, desequilibrio en la tolerancia de la glucosa y complicaciones de la diabetes.
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
NO20073854L (no) Doseringsform og fremgangsmate for vedvarende frigjoring av en substituert pyrazinforbindelse
CL2007003580A1 (es) Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes.
AR068187A1 (es) Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv
NO20082096L (no) Azaindol-2-karboksamidderivativer
ES2531516T3 (es) Uso de escina
CL2008002532A1 (es) Procedimiento de sintesis de un derivado de pirido-[2,1-a]isoquinolina; formas cristalinas de dichos compuestos; y su uso para tratar diabetes, diabetes mellitus, trastorno de la intolerancia a la glucosa.

Legal Events

Date Code Title Description
FC Refusal